Loading…
Alaunos Therapeutics, Inc. is projected to rise to $2.85 by 2027, a +2% move from its current price of $2.81. TCRT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.71 | $2.81 | $2.91 | -0.01% |
| May 30 | $2.68 | $2.81 | $2.95 | -0.01% |
| May 31 | $2.65 | $2.81 | $2.98 | -0.02% |
| Jun 1 | $2.62 | $2.81 | $3.01 | -0.03% |
| Jun 2 | $2.60 | $2.81 | $3.03 | -0.04% |
| Jun 3 | $2.58 | $2.81 | $3.06 | -0.04% |
| Jun 4 | $2.56 | $2.81 | $3.08 | -0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.56 | $2.81 | $3.08 | -0.05% |
| Week 2 | $2.47 | $2.81 | $3.19 | -0.10% |
| Week 3 | $2.40 | $2.81 | $3.29 | -0.15% |
| Week 4 | $2.34 | $2.80 | $3.37 | -0.20% |
| Week 5 | $2.29 | $2.80 | $3.44 | -0.25% |
| Week 6 | $2.24 | $2.80 | $3.50 | -0.30% |
| Week 7 | $2.20 | $2.80 | $3.56 | -0.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alaunos Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Alaunos Therapeutics, Inc. trades with the symbol TCRT in the Healthcare sector. The current price is $2.81 and the market capitalization is $6.86M, with a rank of 5196.
A major floor 23.5% below — a decisive break under it would weaken the trend.
The nearest floor, 15.7% below — buyers have tended to step in here.
The nearest ceiling, 3.9% above — a clean break opens room to run.
A major ceiling 29.9% above — clearing it would confirm fresh momentum.
Key TCRT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TCRT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.49 | Buy | $2.56 | Buy |
| MA 10 | $2.49 | Buy | $2.53 | Buy |
| MA 20 | $2.55 | Buy | $2.57 | Buy |
| MA 50 | $2.78 | Buy | $2.72 | Buy |
| MA 100 | $2.87 | Sell | $2.85 | Sell |
| MA 200 | $2.88 | Sell | $3.06 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.47 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 214.63 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 8.91 | Buy |
| Bollinger %B (20,2) | 1.14 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.52 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 68.26 | Neutral |
| Momentum (10) | 0.18 | Buy |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 2.52 | Buy |
| ADX (14) | 24.24 | Buy |
| ATR (14) | 0.07 | Info |
The near‑term setup is bullish, with RSI14 at 60. Near-term levels show SMA50 at $2.78 and SMA200 at $2.88, framing a narrow range around the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.34 | $2.81 | $3.98 | 0% | Neutral | |
| $2.21 | $2.85 | $3.94 | +2% | Neutral | |
| $2.45 | $3.28 | $4.73 | +17% | Neutral | |
| $3.17 | $4.38 | $6.54 | +56% | Bullish | |
| $3.18 | $4.51 | $6.93 | +60% | Bullish | |
| $3.16 | $4.59 | $7.24 | +63% | Bullish | |
| $3.18 | $4.73 | $7.62 | +68% | Bullish | |
| $3.09 | $4.69 | $7.71 | +67% | Bullish | |
| $3.14 | $4.88 | $8.17 | +74% | Bullish | |
| $3.42 | $5.41 | $9.22 | +93% | Bullish | |
| $4.00 | $6.94 | $12.71 | +147% | Bullish | |
| $8.25 | $16.87 | $34.27 | +501% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.34 | $2.81 | $3.32 | +0.00% |
| June 2026 | $2.40 | $2.83 | $3.44 | +0.87% |
| July 2026 | $2.34 | $2.79 | $3.45 | -1.50% |
| August 2026 | $2.44 | $2.93 | $3.67 | +5.09% |
| September 2026 | $2.54 | $3.08 | $3.90 | +5.13% |
| October 2026 | $2.49 | $3.03 | $3.87 | -1.69% |
| November 2026 | $2.43 | $2.99 | $3.84 | -1.48% |
| December 2026 | $2.49 | $3.07 | $3.98 | +2.89% |
Click any year to see its month-by-month TCRT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Alaunos Therapeutics, Inc.'s 2026 outlook centres on $2.81, within a $2.34 to $3.98 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TCRT could reach as high as $3.94, with a base case around $2.85 and support toward $2.21 — roughly +2% from $2.81. A consolidation phase looks the most probable path here.
Expect TCRT to range from $2.45 to $4.73 through 2028. The $3.28 average target implies a +17% move from current prices. That is up +15% on the projected 2027 average. Price action looks broadly range-bound.
The TCRT price prediction for 2029 points to an average of $4.38 (low $3.17, high $6.54) — a potential gain of +56% on today's $2.81. Buyers look set to stay in control over this stretch.
In 2030, TCRT is projected to trade between $3.18 and $6.93, averaging $4.51 — a potential gain of +60% from today's $2.81. That is up +3% on the projected 2029 average. Momentum favours further upside here.
Alaunos Therapeutics, Inc.'s 2031 outlook centres on $4.59, within a $3.16 to $7.24 range. That is up +2% on the projected 2030 average. That marks a +63% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TCRT could reach as high as $7.62, with a base case around $4.73 and support toward $3.18 — roughly +68% from $2.81. Momentum favours further upside here.
Expect TCRT to range from $3.09 to $7.71 through 2033. The $4.69 average target implies a +67% move from current prices. That is -1% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The TCRT price prediction for 2034 points to an average of $4.88 (low $3.14, high $8.17) — a potential gain of +74% on today's $2.81. Momentum favours further upside here.
In 2035, TCRT is projected to trade between $3.42 and $9.22, averaging $5.41 — a potential gain of +93% from today's $2.81. That is up +11% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Alaunos Therapeutics, Inc.'s 2040 outlook centres on $6.94, within a $4.00 to $12.71 range. That is up +28% on the projected 2035 average. That marks a +147% change versus current levels. Momentum favours further upside here.
By 2050, TCRT could reach as high as $34.27, with a base case around $16.87 and support toward $8.25 — roughly +501% from $2.81. Buyers look set to stay in control over this stretch.
Investing $1,000 in TCRT today (≈ 355.871886 TCRT) could be worth
$6,004.96
+$5,004.96 (+500%) by 2050 · US Dollar
Based on the average projected TCRT price of $16.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TCRTwould be worth at today's price.
$1,000 invested in TCRT on May 27, 2025 (≈ 378.787864 TCRT) would be worth
$1,064.39
+$64.39 (+6.4%) today · 1.06× · US Dollar
Based on a TCRT entry price of $2.64 vs. today's $2.81.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.4 | $1,170.83 | +17.1% |
| 1 month ago | $2.7 | $1,040.74 | +4.1% |
| 3 months ago | $3.14 | $894.9 | -10.5% |
| 6 months ago | $3.34 | $841.32 | -15.9% |
| 1 year ago | $2.64 | $1,064.39 | +6.4% |
| All time (5.0y) ago | $460.5 | $6.1 | -99.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TCRT forecast.
Our base-case forecast reaches $5.60 around 2040.
Implied market cap at $5.60: $13.68M
The multi‑year forecast shows bullish momentum developing after 2026, with 2029 avg $4.38 and 2030 avg $4.51, rising to 2040 avg $6.94 and 2050 avg $16.87. The ROI figures climb from 56% in 2029 to 60.5% in 2030, 147.1% in 2040, and 500.5% in 2050, with sentiment turning bullish from 2029 onward. These are estimates, not guarantees.
Tap a question to reveal the answer.
2030 min $3.18, avg $4.51, max $6.93, ROI 60.5%, sentiment BULLISH.
Forecasts show rising averages over time, with 2030 avg $4.51, 2040 avg $6.94, and 2050 avg $16.87, along with ROI of 60.5%, 147.1%, and 500.5% respectively, but these are estimates, not guarantees.
Yes, the 2050 max is $34.27, with min $8.25 and avg $16.87, ROI 500.5%, sentiment BULLISH.
Current price $2.81; Market cap $6.86M.
Sentiment BULLISH; RSI14 is 60. 30-day range is $2.24 to $3.53; SMA50 $2.78; SMA200 $2.88; support $2.37; resistance $2.92; annualized volatility 70%.
Alaunos Therapeutics, Inc. Community Discussion
0Share your Alaunos Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.